Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.07
-$0.03-1.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.18M | -2.90M | -5.93M | -1.45M | -6.25M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | 0.00 | 0.00 | 0.00 | 4.34M |
| Total Other Non-Cash Items | 1.38M | 2.19M | 4.81M | -- | -- |
| Change in Net Operating Assets | -59.00K | 100.50K | 123.10K | -73.80K | -23.40K |
| Cash from Operations | -863.10K | -605.80K | -1.00M | -1.52M | -1.94M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -132.40K | 132.40K | -- |
| Total Debt Repaid | -- | 0.00 | -433.90K | 0.00 | -101.00K |
| Issuance of Common Stock | -- | 1.04M | 0.00 | 0.00 | 5.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 519.50K | 0.00 | -519.50K |
| Cash from Financing | -- | 1.04M | -46.90K | 132.40K | 5.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -863.10K | 431.50K | -1.05M | -1.39M | 3.27M |